^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Descartes-08
i
Other names: Descartes-08, anti-BCMA chimeric antigen receptor T cell therapy, Descartes08, Descartes 08
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cartesian Therapeutics
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
13d
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
P1/2, N=50, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
Descartes-08
2ms
SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | N=30 --> 6
Enrollment closed • Enrollment change
|
Descartes-08
6ms
Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis (clinicaltrials.gov)
P1/2, N=50, Not yet recruiting, Cartesian Therapeutics
New P1/2 trial
|
Descartes-08
8ms
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Jul 2025
Enrollment closed • Trial primary completion date
|
Descartes-08
10ms
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
Descartes-08
11ms
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Not yet recruiting, Cartesian Therapeutics | Trial completion date: Apr 2026 --> Sep 2027 | Trial primary completion date: Apr 2026 --> Nov 2026
Trial completion date • Trial primary completion date
|
Descartes-08
12ms
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Recruiting, Cartesian Therapeutics
New P3 trial
|
Descartes-08
over1year
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma (clinicaltrials.gov)
P1, N=32, Terminated, Cartesian Therapeutics | Phase classification: P2 --> P1 | Completed --> Terminated; Phase 1 enrollment completed. Further clinical development terminated
Phase classification • Trial termination
|
cyclophosphamide • fludarabine IV • Descartes-08
over1year
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy (clinicaltrials.gov)
P2, N=13, Terminated, Cartesian Therapeutics | N=30 --> 13 | Recruiting --> Terminated; Sponsor decision
Enrollment change • Trial termination
|
Descartes-08
almost2years
SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P2, N=30, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
Descartes-08
almost2years
SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P2, N=30, Not yet recruiting, Cartesian Therapeutics | Initiation date: Nov 2023 --> Feb 2024
Trial initiation date
|
Descartes-08
almost2years
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) (clinicaltrials.gov)
P2, N=30, Recruiting, Cartesian Therapeutics | Trial completion date: Dec 2023 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Mar 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
Descartes-08
Share via
